Aurobindo has received the Food and Drug Administration’s clearance for ambrisentan tablets, 5 mg and 10 mg, a product which is the generic of Gilead Sciences’ Letairis.
[Read more: Aurobindo obtains FDA OK for generic Lioresal]
The medication is indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise ability and delay clinical worsening. It also is indicated in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.
Ambrisentan tablets have a market value of roughly $58 million for the 12 months ending May 2022, according to IQVIA.
[Read more: Aurobindo obtains FDA approval for generic Colcrys]